Pfizer: new positive data against Omicron

(CercleFinance.com) - Pfizer and BioNTech announce positive results for an analysis examining the immune response induced by their bivalent anti-Covid-19 vaccine, which is adapted to Omicron BA.
4/BA.5 against new Omicron sublines, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1.

One month after a 30 μg booster dose of the Omicron-adapted bivalent vaccine, neutralising antibody titers against the emerging Omicron sublineages increased 3.2-4.8-fold compared with the original vaccine, the company said.

Neutralising antibody titres against Omicron sublineages BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1 increased 4.8 to 11.1-fold compared to pre-booster levels after a 30 μg booster dose of the bivalent vaccine.


Copyright (c) 2022 CercleFinance.com. All rights reserved.